Omnicell (OMCL) Tops Q1 EPS by 17c, Revenues Beat; Offers FY21 EPS/Revenues Mid-Point Outlook Above Consensus, Offers 2Q Revs. View Above Est.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. DPZ
7. NAVN
8. NVDA
9. DFTX
10. META

Go back to Omnicell (OMCL) Tops Q1 EPS by 17c, Revenues Beat; Offers FY21 EPS/Revenues Mid-Point Outlook Above Consensus, Offers 2Q Revs. View Above Est.

Omnicell Announces Financial Results for First Quarter 2021

April 29, 2021 4:01 PM EDT

Record revenues of $252 million, an increase of 10% from the prior year period
GAAP net income per diluted share of $0.30, Non-GAAP net income per diluted share of $0.83
Added new long-term, sole-source partnership agreements with Top 300 U.S. Health Systems

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its first quarter ended March 31, 2021.

GAAP Results

Total revenues for the first quarter of 2021 were $251.8... More